Medicus Pharma (MDCX) Competitors $2.58 +0.13 (+5.31%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsTrends MDCX vs. CNTX, RGLS, MNOV, SKYE, IMUX, DERM, VERU, RANI, ANRO, and COYAShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Context Therapeutics (CNTX), Regulus Therapeutics (RGLS), MediciNova (MNOV), Skye Bioscience (SKYE), Immunic (IMUX), Journey Medical (DERM), Veru (VERU), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical preparations" industry. Medicus Pharma vs. Context Therapeutics Regulus Therapeutics MediciNova Skye Bioscience Immunic Journey Medical Veru Rani Therapeutics Alto Neuroscience Coya Therapeutics Medicus Pharma (NASDAQ:MDCX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Is MDCX or CNTX more profitable? Medicus Pharma's return on equity of 0.00% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A N/A N/A Context Therapeutics N/A -58.76%-55.80% Do analysts prefer MDCX or CNTX? Medicus Pharma currently has a consensus price target of $10.00, indicating a potential upside of 287.60%. Context Therapeutics has a consensus price target of $6.80, indicating a potential upside of 566.67%. Given Context Therapeutics' higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Medicus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in MDCX or CNTX? 14.0% of Context Therapeutics shares are held by institutional investors. 3.0% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to MDCX or CNTX? In the previous week, Medicus Pharma had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 1.94 beat Medicus Pharma's score of 1.00 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation & earnings, MDCX or CNTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/AN/AN/AN/AContext TherapeuticsN/AN/A-$23.96M-$0.91-1.12 Does the MarketBeat Community favor MDCX or CNTX? Context Therapeutics received 17 more outperform votes than Medicus Pharma when rated by MarketBeat users. However, 100.00% of users gave Medicus Pharma an outperform vote while only 72.00% of users gave Context Therapeutics an outperform vote. CompanyUnderperformOutperformMedicus PharmaOutperform Votes1100.00% Underperform VotesNo VotesContext TherapeuticsOutperform Votes1872.00% Underperform Votes728.00% SummaryContext Therapeutics beats Medicus Pharma on 6 of the 10 factors compared between the two stocks. Ad Paradigm Press Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.99M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / BookN/A5.094.784.78Net IncomeN/A$151.83M$120.31M$225.60M7 Day Performance-6.18%-2.13%-1.92%-1.23%1 Month PerformanceN/A-3.10%11.50%3.36%1 Year PerformanceN/A11.54%30.59%16.60% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus PharmaN/A$2.58+5.3%$10.00+287.6%N/A$27.99MN/A0.00N/AAnalyst ForecastCNTXContext Therapeutics2.9747 of 5 stars$1.50-3.8%$6.80+353.3%+1.0%$112.50MN/A-1.717Positive NewsGap DownRGLSRegulus Therapeutics2.7405 of 5 stars$1.70+3.7%$10.80+535.3%+20.5%$111.35MN/A-1.5330News CoveragePositive NewsMNOVMediciNova2.1642 of 5 stars$2.17-4.0%$9.00+314.7%+43.7%$110.84M$1M-10.3310Analyst ForecastPositive NewsSKYESkye Bioscience2.1878 of 5 stars$3.62-0.8%$18.67+415.7%-10.6%$109.82MN/A0.0011News CoveragePositive NewsIMUXImmunic2.933 of 5 stars$1.21-2.4%$11.80+875.2%-20.6%$109.00MN/A-1.0170Positive NewsDERMJourney Medical2.548 of 5 stars$5.18-4.8%$9.38+81.0%N/A$108.21M$79.18M-5.5190VERUVeru1.9737 of 5 stars$0.73+1.4%$4.00+444.5%-3.5%$107.53M$16.30M-1.53189Earnings ReportAnalyst ForecastRANIRani Therapeutics3.4519 of 5 stars$1.86-2.1%$11.71+529.8%-55.1%$106.56M$2.72M-1.79110ANROAlto Neuroscience3.2643 of 5 stars$3.89-4.0%$20.00+414.1%N/A$104.91M$210,000.000.00N/AGap UpCOYACoya Therapeutics2.1484 of 5 stars$6.21+1.5%$16.25+161.7%-23.7%$103.75M$9.55M-9.426Analyst ForecastPositive NewsGap Down Related Companies and Tools Related Companies Context Therapeutics Alternatives Regulus Therapeutics Alternatives MediciNova Alternatives Skye Bioscience Alternatives Immunic Alternatives Journey Medical Alternatives Veru Alternatives Rani Therapeutics Alternatives Alto Neuroscience Alternatives Coya Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MDCX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDCX Stock Alerts